Patents by Inventor Jeffrey K. Pullen

Jeffrey K. Pullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7378099
    Abstract: The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides for fusions of HPV E6 and E7 in which the E6 and/or E7 contains one or more mutations. These mutations abrogate the transformation activity of these oncogenic proteins and, thus, confer safety to the E6/E7 fusions. In addition, these fusions maintain or increase the immunogenic efficacy of E6 and E7. Any gene or protein delivery method can be used to deliver or package the immunogenic compositions of the present invention.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: May 27, 2008
    Assignee: Wyeth
    Inventors: Maria Cristina Cassetti, Larry Smith, Jeffrey K. Pullen, Susan P. McElhiney
  • Patent number: 7223408
    Abstract: The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides for fusions of HPV E6 and E7 in which the E6 and/or E7 contains one or more mutations. These mutations abrogate the transformation activity of these oncogenic proteins and, thus, confer safety to the E6/E7 fusions. In addition, these fusions maintain or increase the immunogenic efficacy of E6 and E7. Any gene or protein delivery method can be used to deliver or package the immunogenic compositions of the present invention.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: May 29, 2007
    Assignee: Wyeth Holdings Corporation
    Inventors: Maria Cristina Cassetti, Larry Smith, Jeffrey K. Pullen, Susan P. McElhiney
  • Patent number: 6764686
    Abstract: This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector.
    Type: Grant
    Filed: July 21, 1998
    Date of Patent: July 20, 2004
    Assignee: Baxter International Inc.
    Inventors: Conceicao Minetti, Francis Michon, Jeffrey K. Pullen, Mary Ellen Polvino-Bodnar, Shu-Mei Liang, Joseph Y. Tai
  • Publication number: 20010014332
    Abstract: This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector.
    Type: Application
    Filed: July 21, 1998
    Publication date: August 16, 2001
    Applicant: NORTH AMERICAN VACCINE, INC.
    Inventors: CONCEICAO MINETTI, FRANCIS MICHON, JEFFREY K. PULLEN, MARYELLEN POLVINO-BODNAR, SHU-MEI LIANG, JOSEPH Y. TAI
  • Patent number: 6153406
    Abstract: The present invention relates, in general, to a method of expressing the outer membrane protein P2 from Haemophilus influenzae type b (Hib-P2) and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein P2 from Haemophilus influenzae type b or fusion protein thereof in E. coli wherein the Hib-P2 protein or fusion protein comprises more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of Hib-P2 protein and fusion protein thereof.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: November 28, 2000
    Assignee: North American Vaccine, Inc.
    Inventors: Joseph Y. Tai, Jeffrey K. Pullen, Thomas Soper, Shu-Mei Liang, Milan S. Blake
  • Patent number: 6013267
    Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins and fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.
    Type: Grant
    Filed: February 11, 1997
    Date of Patent: January 11, 2000
    Assignees: North American Vaccine, Inc., The Rockefeller University
    Inventors: Milan S. Blake, Joseph Y. Tai, Huilin L. Qi, Shu-Mei Liang, Lucjan J.J. Hronowski, Jeffrey K. Pullen
  • Patent number: 5879686
    Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins and fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: March 9, 1999
    Assignees: North American Vaccine, Inc., The Rockefeller University
    Inventors: Milan S. Blake, Joseph Y. Tai, Huilin L. Qi, Shu-Mei Liang, Lucjan J. J. Hronowski, Jeffrey K. Pullen
  • Patent number: 5747287
    Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins and fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.
    Type: Grant
    Filed: June 17, 1997
    Date of Patent: May 5, 1998
    Assignees: North American Vaccine, Inc., The Rockefeller University
    Inventors: Milan S. Blake, Joseph Y. Tai, Huilin L. Qi, Shu-Mei Liang, Lucjan J. J. Hronowski, Jeffrey K. Pullen
  • Patent number: 5439808
    Abstract: The present invention relates, in general, to a method for the high level expression of the outer membrane protein meningococcal group B porin proteins and fusion proteins thereof. In particular, the present invention relates to a method of expressing the outer membrane protein meningococcal group B porin proteins in E. coli wherein the meningococcal group B porin proteins yard fusion proteins thereof comprise more than 2% of the total protein expressed in E. coli. The invention also relates to a method of purification and refolding of the meningococcal group B porin proteins and fusion proteins thereof and to their use in vaccines.
    Type: Grant
    Filed: July 23, 1993
    Date of Patent: August 8, 1995
    Assignees: North American Vaccine, Inc., The Rockefeller University
    Inventors: Milan S. Blake, Joseph Y. Tai, Huilin L. Qi, Shu-Mei Liang, Lucjan J. J. Hronowski, Jeffrey K. Pullen